FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan

      Novo Nordisk Achieves Success in Phase 3 Trial for Sickle Cell Disease Treatment

      Novo Nordisk has announced that its phase 3 HIBISCUS trial for etavopivat, a treatment for sickle cell disease, successfully met both of its co-primary endpoints. The trial demonstrated that etavopivat significantly reduced the frequency of vaso-occlusive crisis events and improved hemoglobin response among participants.

      The company intends to seek regulatory approval for etavopivat in the second half of 2026. This move marks a strategic expansion for Novo Nordisk, which is primarily known for its diabetes and obesity treatments, into the field of blood disorders.

      The success of etavopivat in clinical trials is expected to attract interest from investors, particularly as the company aims to diversify its portfolio beyond its traditional focus areas.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud